Sotyktu (Deucravacitinib) Post-Marketing Surveillance in Korean Patients With Moderate-to-Severe Plaque Psoriasis
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
View:
• Adult participants ≥19 years of age
• Diagnosis of moderate-to-severe plaque psoriasis
• Candidate for phototherapy or systemic therapy
• Will begin deucravacitinib according to approved product label
Locations
Other Locations
Republic of Korea
Local Institution - 0001
WITHDRAWN
Seoul
Novotech Laboratory Korea Co., Ltd.
RECRUITING
Seoul
Contact Information
Primary
BMS Study Connect Contact Center www.BMSStudyConnect.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2024-08-21
Estimated Completion Date: 2028-09-30
Participants
Target number of participants: 505
Treatments
Participants diagnosed with moderate-to-severe plaque psoriasis
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb